Literature DB >> 10776799

Accessory function and costimulatory molecule expression of alveolar macrophages in patients with pulmonary tuberculosis.

A Somoskövi1, G Zissel, M W Ziegenhagen, M Schlaak, J Müller-Quernheim.   

Abstract

An effective immune response against M. tuberculosis requires a coordinated interaction of alveolar macrophages (AM) and lymphocytes. Secondary signals, such as accessory function (AF) of antigen presenting cells and interaction of costimulatory molecules are also important for T cell activation. In the present study we determined the AF and the expression of CD11a, CD54, CD58, CD80, CD86 and HLA-DR costimulatory molecules by AMs lavaged from patients with pulmonary tuberculosis and controls. We hypothesized that alterations in AF and costimulatory molecule expression may influence the presentation of tuberculosis. Therefore these parameters were also correlated with the radiographic extension of the disease. AMs of patients with tuberculosis exhibited an increased AF and a significantly increased expression of co-stimulatory molecules compared with controls. Furthermore, we observed that the expression of CD54 (ICAM-1) decreased with the course of the disease. We conclude that the infection by M. tuberculosis results in an increased AF of AMs and the activity of AMs remains uninfluenced by the extension of the disease. Clear-cut changes of patterns of costimulatory molecule expression by AMs could not be observed with the progression of tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10776799     DOI: 10.1016/S0171-2985(00)80097-2

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  1 in total

1.  CD11c+ antigen presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and capabilities to activate naïve and antigen-primed T cells.

Authors:  Kapilan Kugathasan; Elizabeth K Roediger; Cherrie-Lee Small; Sarah McCormick; Pingchang Yang; Zhou Xing
Journal:  BMC Immunol       Date:  2008-08-13       Impact factor: 3.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.